🧬 A major step forward in pancreatic cancer treatment The…
🧬 A major step forward in pancreatic cancer treatment
The FDA has approved Rasonque (daraxonrasib), a first-in-class RAS inhibitor for previously treated metastatic pancreatic cancer.
In a 500-patient clinical trial, median overall survival reached 13.2 months vs. 6.7 months with standard chemotherapy.
What makes this especially significant is the ability to target RAS—a key driver of tumour growth and one of the most challenging targets in cancer drug development.
A promising milestone for precision oncology and targeted cancer therapy.
#Pharma #Oncology #DrugDevelopment #PrecisionMedicine #CancerResearch #Healthcare
Source: U.S. FDA — FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer
www.fda.gov
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.
3 likes · 0 comments · 8 views